ORKA
Oruka TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive clinical readout, a partnering deal, or early commercial traction could re-rate the stock significantly above the close; upside is concentrated in near-term data/partnering events.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -11.4.
What can break
Clinical failure, a short cash runway forcing dilutive financing, or regulatory delays would likely produce material downside toward the bear target.
Momentum
80
Value
42
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $27.08 · Bull $37.91 · Bear $16.25
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-17 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $58.25
Why
Momentum80 · Δ7d -11.4
Value42 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
80
34% active weight
Current posture
7d trendSoftening
Δ7d
-11.4
Δ21d
-20.2
Value
42
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade D. Momentum 79.8 / Value 41.9 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$3.32B
Beta
-0.37
Shares Out
48.41M
P/E (TTM) · Derived
-13.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-34.78
Rev YoY
-
EPS YoY
+64.0%
Gross Margin
-
Op Margin
-
Net Debt
-$375.65M
Current Ratio
16.94
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology